Kishi, Masahiro
Hirai, Fumihito http://orcid.org/0000-0002-5493-5675
Takatsu, Noritaka
Hisabe, Takashi
Takada, Yasumichi
Beppu, Tsuyoshi
Takeuchi, Ken
Naganuma, Makoto
Ohtsuka, Kazuo
Watanabe, Kenji
Matsumoto, Takayuki
Esaki, Motohiro
Koganei, Kazutaka
Sugita, Akira
Hata, Keisuke
Futami, Kitarou
Ajioka, Yoichi
Tanabe, Hiroshi
Iwashita, Akinori
Shimizu, Hirotaka
Arai, Katsuhiro
Suzuki, Yasuo
Hisamatsu, Tadakazu
Funding for this research was provided by:
Study Group on Intractable Diseases, the Health and Labour Sciences Research Grants
Article History
Received: 4 November 2021
Accepted: 6 February 2022
First Online: 2 March 2022
Declarations
:
: Any financial relationship with enterprises, businesses or academic institutions in the subject matter or materials discussed in the manuscript are listed as follows; (1) those from which the authors, the spouse, partner or immediate relatives of authors, have received individually any income, honoraria or any other types of remuneration; Abbvie GK, EA Pahrma Co., Ltd, Janssen Pharmaceutical K.K, Mochida Pharmaceutical Co., Ltd, Tanabe Mitsubishi Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd, Kyorin Pharmaceutical Co., Ltd, Pfizer Japan Inc. and Kissei Pharmaceutical Co., Ltd, Nichi-iko Paermaceutical Co., Ltd, JIMRO Co., Ltd and (2) those from which the academic institutions of the authors received support (commercial/academic cooperation); Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Abbvie GK, EA Pahrma Co., Ltd, Eisai Co., Ltd, Otsuka Pharmaceutical Co., Ltd, Kissei Pharmaceutical Co., Ltd, Nippon Kayaku Co., Ltd, Mochida Pharmaceutical Co., Ltd, Tanabe Mitsubishi Pharmaceutical Co., Ltd, Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd, EP-CRSU Co,. Ltd, ZERIA Pharmaceutical Co., Ltd, Alfresa Pharma Co. Ltd, JIMRO Co., Ltd. Daichi-Sankyo Co., Ltd, Kyorin Pharmaceutical Co., Ltd.